First Ever Bonus Issue: Dr. Lal PathLabs To Declare Bonus, Dividend On Oct-31; BUY This Pharma Stock?

Dr. Lal PathLabs Ltd., a BSE 500 listed company, witnessed strong buying sentiment on October 27. The bull trend comes ahead of Dr Lal's upcoming bonus and dividend proposal. The company's board of directors are scheduled to meet on October 31. If the board approved, then Dr Lal will deliver its first ever bonus issue. The details of upcoming dividends and bonus will be keenly watched.

Dr. Lal PathLabs Ltd Share Price

After market hours on October 27, Dr. Lal PathLabs share price closed at Rs 3141.75 apiece, up by Rs 97.25 or 3.19% on BSE, with market cap of Rs 11,964.68 crore. The stock's 52-week high and low is at Rs 3,542.60 apiece and Rs 2,295.10 apiece respectively.

YTD, the healthcare stock gains nearly 3%. However, in the long term, the stock's performance is healthy with 37% upside in 5-years span. But Dr Lal's all-time returns is whopping 251.27%.

Dr. Lal PathLabs Ltd Q2 Results:

In its regulatory filing, Dr. Lal PathLabs' board of directors is scheduled to be held on Friday, October 31, 2025 to consider and approve Un-audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Half Year ended September 30, 2025.

Dr. Lal PathLabs Ltd Dividends:

The company will also consider the announcement of second interim dividend for FY26, on October 31. So far, Dr Lal holds a healthy record of rewarding investors with dividend payouts.

For FY26, the company paid up to Rs 6 per share as first interim dividend and its ex-date was in August this year.

So far, the company delivered 24 dividends since July 20, 2016, as per Trendlyne data. In the past 12 months, the company rewarded a whopping Rs 24 dividend per share. Currently, it has a dividend yield of 0.76%.

Dr. Lal PathLabs Ltd Bonus Issue:

On October 31st, the company's board will consider issuance of bonus shares in accordance with the applicable provisions and subject to approval of Shareholders of the Company.

A bonus issue is the distribution of free shares by the company to the existing shareholders. A company may decide to distribute additional shares as an alternative to dividend payout. In a bonus issue, the number of shares increases, but the value of the investment remains the same, as per Zerodha.

Dr. Lal PathLabs Ltd Recommendations:

The consensus recommendation from 24 analysts for Dr. Lal Pathlabs Ltd. is HOLD, as per Trendlyne data.

Earlier this month, analysts at Kotak Institutional Equities recommended ADD on Dr Lal for a target price of Rs 3,515 per share. This comes after the brokerage noted that DLPL appears to have experimented a bit with Suburban's pricing over the past six months, with the company now completely rescinding a recent price hike taken in Mumbai and Pune in 1QFY26.

"Although the intensity of price-led competition has decreased over the past 2.5 years, the pricing differential between listed incumbents and online players stays elevated at ~2X (albeit lower than in the past). While we expect the sheer higher quantum of organized competitors to still restrict a significant volume bounce back, we expect organic test volume growth for DLPL," said the analysts.

About Dr Lal Pathlabs Ltd:

Established in 1949, Dr Lal PathLabs today is the largest and most respected diagnostic service provider in the country. It has a proven track record of over six decades for strict adherence to international standards and benchmarks. Dr Lal PathLabs offers widest test menu and has a pan India presence in all important cities and towns of India, in the form of state-of-the-art laboratories and patient service centres.

Disclaimer: The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.